Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume 55, Issue 2, Pages 230-239
Publisher
Wiley
Online
2014-09-06
DOI
10.1002/jcph.395
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam
- (2014) Myra Wooley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections
- (2014) Christopher Lucasti et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)
- (2014) Helio S. Sader et al. JOURNAL OF INFECTION
- Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in anIn VitroInfection Model
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2011-2012)
- (2013) David J. Farrell et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane
- (2013) Brian VanScoy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- How should we dose antibiotics for pneumonia in the ICU?
- (2013) Andrew A. Udy et al. CURRENT OPINION IN INFECTIOUS DISEASES
- In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice
- (2012) W. A. Craig et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
- (2012) Benjamin Miller et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
- (2012) G. Chandorkar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacokinetics of Beta-Lactam Antibiotics in Patients with Intra-Abdominal Disease: A Structured Review
- (2012) Syamhanin Adnan et al. Surgical Infections
- Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes
- (2011) Helio S. Sader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14– and CTX-M-15–producing Escherichia coli and Klebsiella pneumoniae
- (2011) Emilia Titelman et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding Proteins of Pseudomonas aeruginosa
- (2010) B. Moya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Safety of CXA-101, a New Antipseudomonal Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and Multiple-Dose Intravenous Infusions
- (2010) Y. Ge et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started